Pliant Therapeutics, Inc. (PLRX)
Nasdaq · Healthcare · Biotechnology
$1.03−0.48%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $63.8M
- 52-week range
- $1.02 – $1.95
- 52-week change
- −30.54%
- EPS (trailing)
- −$1.50
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $0K
- Net income
- $149M
- Diluted EPS
- −$2.43
- Free cash flow
- −$129M
From the company’s annual report on SEC EDGAR.
About Pliant Therapeutics, Inc.
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Headquarters: South San Francisco, United States · 49 employees · pliantrx.com